Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases with therapies by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl for the treatment of patients with chronic kidney disease caused by Alport syndrome; and for a form of pulmonary arterial hypertension associated with connective tissue disease. It is also developing omaveloxolone that is Phase II clinical trial for the treatment of patients with Friedreich's ataxia. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Irving, Texas.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RETA
CUSIPN/A
Phone972-865-2219
Debt
Debt-to-Equity Ratio-0.47
Current Ratio3.09
Quick Ratio3.09
Price-To-Earnings
Trailing P/E Ratio-37.55
Forward P/E Ratio-31.67
P/E GrowthN/A
Sales & Book Value
Annual Sales$48.06 million
Price / Sales46.15
Cash FlowN/A
Price / CashN/A
Book Value($5.62) per share
Price / Book-13.30
Profitability
EPS (Most Recent Fiscal Year)($1.99)
Net Income$-47,670,000.00
Net Margins-85.00%
Return on EquityN/A
Return on Assets-34.32%
Miscellaneous
Employees93
Outstanding Shares29,680,000
Market Cap$1.68 billion
Reata Pharmaceuticals (NASDAQ:RETA) Frequently Asked Questions
What is Reata Pharmaceuticals' stock symbol?
Reata Pharmaceuticals trades on the NASDAQ under the ticker symbol "RETA."
How were Reata Pharmaceuticals' earnings last quarter?
Reata Pharmaceuticals Inc (NASDAQ:RETA) announced its quarterly earnings results on Wednesday, August, 8th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.74) by $0.34. The firm had revenue of $7.57 million for the quarter, compared to analysts' expectations of $9.11 million. View Reata Pharmaceuticals' Earnings History.
When is Reata Pharmaceuticals' next earnings date?
What price target have analysts set for RETA?
5 brokerages have issued twelve-month target prices for Reata Pharmaceuticals' stock. Their forecasts range from $44.00 to $116.00. On average, they expect Reata Pharmaceuticals' stock price to reach $86.75 in the next twelve months. This suggests a possible upside of 16.1% from the stock's current price. View Analyst Price Targets for Reata Pharmaceuticals.
What is the consensus analysts' recommendation for Reata Pharmaceuticals?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Reata Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Reata Pharmaceuticals.
Who are some of Reata Pharmaceuticals' key competitors?
Some companies that are related to Reata Pharmaceuticals include Ionis Pharmaceuticals (IONS), GALAPAGOS NV/S (GLPG), United Therapeutics (UTHR), Catalent (CTLT), Dr.Reddy's Laboratories (RDY), Ligand Pharmaceuticals (LGND), FibroGen (FGEN), Loxo Oncology (LOXO), Agios Pharmaceuticals (AGIO), HUTCHISON CHINA/S (HCM), Taro Pharmaceutical Industries (TARO), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals PLC- (GWPH), Madrigal Pharmaceuticals (MDGL) and Endo International (ENDP).
Who are Reata Pharmaceuticals' key executives?
Reata Pharmaceuticals' management team includes the folowing people:
- Mr. J. Warren Huff, Chairman, CEO & Pres (Age 64)
- Dr. Colin J. Meyer, Chief Medical Officer & VP of Product Devel. (Age 39)
- Dr. Keith W. Ward, VP & Chief Devel. Officer (Age 48)
- Mr. Jason D. Wilson, CFO & VP of Strategy (Age 48)
- Ms. Elaine Castellanos, VP of Fin. & Accounting and Principal Accounting Officer
When did Reata Pharmaceuticals IPO?
(RETA) raised $60 million in an initial public offering (IPO) on Thursday, May 26th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and Company and Piper Jaffray served as the underwriters for the IPO.
Has Reata Pharmaceuticals been receiving favorable news coverage?
News headlines about RETA stock have been trending somewhat positive on Tuesday, according to Accern. The research group scores the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Reata Pharmaceuticals earned a media and rumor sentiment score of 0.09 on Accern's scale. They also assigned press coverage about the company an impact score of 47.21 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future. View Recent Headlines for Reata Pharmaceuticals.
Who are Reata Pharmaceuticals' major shareholders?
Reata Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.74%), Emerald Advisers Inc. PA (2.08%), Emerald Mutual Fund Advisers Trust (1.86%), FMR LLC (1.79%), Point72 Asset Management L.P. (0.76%) and King Luther Capital Management Corp (0.36%). Company insiders that own Reata Pharmaceuticals stock include A/S Novo, Abbvie Inc, Cpmg Inc, Elaine Castellanos, Jack Nielsen, James Edward Bass, James W Traweek Jr, Keith Wayne Ward and R Kent Mcgaughy Jr. View Institutional Ownership Trends for Reata Pharmaceuticals.
Which major investors are selling Reata Pharmaceuticals stock?
RETA stock was sold by a variety of institutional investors in the last quarter, including Prosight Management LP, FMR LLC, P.A.W. Capital Corp, Citadel Advisors LLC, Alps Advisors Inc., Alps Advisors Inc. and Alps Advisors Inc.. Company insiders that have sold Reata Pharmaceuticals company stock in the last year include Elaine Castellanos and Keith Wayne Ward. View Insider Buying and Selling for Reata Pharmaceuticals.
Which major investors are buying Reata Pharmaceuticals stock?
RETA stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Point72 Asset Management L.P., Emerald Advisers Inc. PA, GAM Holding AG, Sio Capital Management LLC, King Luther Capital Management Corp, Engineers Gate Manager LP and First Manhattan Co.. Company insiders that have bought Reata Pharmaceuticals stock in the last two years include Cpmg Inc, Jack Nielsen, James Edward Bass, James W Traweek Jr and R Kent Mcgaughy Jr. View Insider Buying and Selling for Reata Pharmaceuticals.
How do I buy shares of Reata Pharmaceuticals?
Shares of RETA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Reata Pharmaceuticals' stock price today?
One share of RETA stock can currently be purchased for approximately $74.73.
How big of a company is Reata Pharmaceuticals?
Reata Pharmaceuticals has a market capitalization of $1.68 billion and generates $48.06 million in revenue each year. The company earns $-47,670,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis. Reata Pharmaceuticals employs 93 workers across the globe.
How can I contact Reata Pharmaceuticals?
Reata Pharmaceuticals' mailing address is 2801 GATEWAY DRIVE SUITE 150, IRVING TX, 75063. The company can be reached via phone at 972-865-2219 or via email at [email protected]
MarketBeat Community Rating for Reata Pharmaceuticals (NASDAQ RETA)
MarketBeat's community ratings are surveys of what our community members think about Reata Pharmaceuticals and other stocks. Vote "Outperform" if you believe RETA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RETA will underperform the S&P 500 over the long term. You may vote once every thirty days.
